|
Variable | Results | value, females vs. males |
All | Females | Males |
|
Gender | 581 | 309 (53.2%) | 272 (46.8%) | n.a. |
Age (years±SD) | 81.2±10.1 | 82.3±0.6 | 80±0.5 | 0.006 |
In-hospital stay (days±SD) | 13.1±10.8 | 12.6±0.6 | 13.5±0.6 | 0.31 |
CKD stage (% of all individuals) | Females: II—1.9, IIIa—14.3, IIIb—36.4, IV—37.1, V—9.2 | n.a. |
Males: II—2.9, IIIa—12.7, IIIb—35.1, IV—39.6, V—10.2 |
CKD diagnosis documented (%) | 90.0 | 89.3 | 92.6 | 0.16 |
CKD etiology documented (%) | 82.1 | 79.9 | 84.6 | 0.14 |
Diagnosis of hypertension documented (%) | 59.2 | 57.9 | 60.7 | 0.5 |
RAS inhibitor at the time of discharge (no+/−ACE inhibitor—sartan in %) | No | 26.5 | 26.5 | 26.5 | 0.72 |
ACE i | 38.9 | 37.5 | 40.4 |
sartan | 34.6 | 35.9 | 33.1 |
Quantification of serum phosphate (%) | 12.9 | 13.9 | 11.8 | 0.4 |
Quantification of PTH (%) | 5.5 | 5.8 | 5.1 | 0.72 |
Quantification of 25-OH-D3 (%) | 6 | 6.8 | 5.1 | 0.4 |
Phosphate binder recommended (%) | 3.6 | 4.5 | 2.6 | 0.2 |
Vitamin D recommended (%) | 23.1 | 27.5 | 18 | 0.007 |
Diagnosis of CKD-MBD documented (%) | 0.3 | 0.3 | 0.4 | 0.92 |
Quantification of ferritin (%) | 14.6 | 13.3 | 16.2 | 0.32 |
Quantification of transferrin saturation (%) | 13.6 | 12.9 | 14.3 | 0.62 |
Iron therapy recommended if necessary (%) | 12.7 | 10 | 15.8 | 0.03 |
Erythropoietin therapy recommended if necessary (%) | 1 | 0.6 | 1.5 | 0.32 |
Diagnosis of renal anemia documented (%) | 3.8 | 3.9 | 3.7 | 0.89 |
Assessment of proteinuria (%) | 10.3 | 10.4 | 10.3 | 0.98 |
Blood gas analysis performed (%) | 55.1 | 53.4 | 57 | 0.38 |
Bicarbonate therapy recommended (%) | 5 | 4.8 | 4 | 0.32 |
Nephrology follow-up recommended (%) | 27 | 25.6 | 28.7 | 0.4 |
|